1.Updates on microRNA in body fluids.
Chinese Journal of Pathology 2010;39(6):424-427
2.Efficacy and safety of phosphoric acid phosphate combined metformin in the treatment of diagnosis of type 2 diabetes mellitus
Haiyan YAN ; Ming ZHAO ; Chun LUO
Chinese Journal of Biochemical Pharmaceutics 2017;37(4):198-200
Objective To evaluate the efficacy and safety of phosphoric acid phosphate combined metformin in the treatment of diagnosis of type 2 diabetes mellitus.Methods A total of 86 cases with diagnosis of type 2 diabetes mellitus included in this study were dividing into control group and experiment group with each 43 cases.The patients in the both groups were give regular treatment.Patients in the control group were given metformin hydrochloride sustained release tablets 500mg by oral administration with 3 times a day and patients in the experiment group revieved phosphoric acid phosphate by oral administration with once a day.A cycle of 2 groups of patients were 28d,a total of 3 cycles of treatment.The ADP,APAF1,D25-(OH)D3),CysC and adverse drug reactions were compared between the two groups.Results The clinical efficacy in experiment group was 93.02%,which significant higher than that in control group 76.74%(P<0.05).The serum level of ADP,APAF1 and CysC decreased after treatment with experiment group much lower than the control group(P<0.05).The serum D25-(OH)D3l elevated in the two groups with experiment group much higher than the control group(P<0.05).The adverse drug reactions was not statistically different between the two groups.Conclusion Phosphoric acid phosphate combined metformin in the treatment of diagnosis of type 2 diabetes mellitus was effective with high safety.
4.Explore Xueshuan Xinmaining tablet effecting on treatment outcome of coronary heart disease based on propensity score.
Yuan LI ; Yan-ming XIE ; Yan LIU ; Wei ZHAO
China Journal of Chinese Materia Medica 2015;40(24):4791-4796
Xueshuan Xinmaining tablet is a Chinese patent medicine for treating chest pain caused by blood stasis. It is widely used in clinical prevention and treatment of coronary heart disease. In order to understand the treatment effect of Xueshuan Xinmaining tablet in patients with coronary heart disease, we extracted electronic medical record data from 18 large hospitals nationwide. We matched the coronary artery disease patients with or without Xueshuan Xinmaining tablet treatment on gender, age, condition at admission and whether combined with cardiac insufficiency on a one to one ratio. After matching, both groups, patients using Xueshuan Xinmaining tablet (group A) and patients not using Xueshuan Xinmaining tablet (group B), ended up with 1,122 people. In order to evaluate the effectiveness of treatment, the endpoint of effective group was defined as "cure" and "better" while the endpoint of invalid group was defined as "invalid" and "death". Chi-square test showed a statistical significant difference (P < 0.05) between the two groups of patients with coronary heart disease, with a higher efficiency in Xueshuan Xinmaining group. Classic logistic regression analysis showed no statistical significant difference between the two groups on treatment outcome efficiency. Generalized boosted models (GBM) and propensity score (PS) weighted Logistic regression were then applied to balance 45 variables between the two groups. The results showed a regression coefficient greater than 0 and a statistical significant difference (P < 0.05) between the two groups. Based on the existing results of the analysis, we considered that coronary heart disease patients using Xueshuan Xinmaining tablet had a higher efficiency in clinical efficiency than the patients not using Xueshuan Xinmaining tablet. Since this study did not certainly eliminate all the possible confounders and patients from the hospitals included in this study were not yet well represent the overall situation of the source population, the study conclusion only provided drug use reference for clinical doctors for coronary heart disease. Large randomized controlled trials needs to be done for more reliable results to guide clinical rational and effective medication.
Adolescent
;
Adult
;
Aged
;
Coronary Artery Disease
;
drug therapy
;
Drugs, Chinese Herbal
;
therapeutic use
;
Female
;
Humans
;
Logistic Models
;
Male
;
Middle Aged
;
Propensity Score
;
Tablets
5."Zhou's needling on the cross meridian" combined with active reperfu- sion for 31 cases of soft tissue injury.
Jing LI ; Yu-Yan ZHOU ; Zhao-Ming CHEN
Chinese Acupuncture & Moxibustion 2014;34(12):1189-1190
Acupuncture Points
;
Acupuncture Therapy
;
Adolescent
;
Adult
;
Aged
;
Female
;
Humans
;
Male
;
Meridians
;
Middle Aged
;
Soft Tissue Injuries
;
therapy
;
Young Adult
7.Reliability and validity of Stanford Presenteeism Scale Chinese version.
Fang ZHAO ; Jun-ming DAI ; Shi-yong YAN
Chinese Journal of Industrial Hygiene and Occupational Diseases 2010;28(9):679-682
Adult
;
Efficiency
;
Female
;
Humans
;
Male
;
Middle Aged
;
Psychometrics
;
Surveys and Questionnaires
8.Analysis of influencing factors on adverse reaction of Shengfu injection based on prospective active safety monitoring.
Zhi-fei WANG ; Wei ZHAO ; Yin ZHANG ; Yan-ming XIE
China Journal of Chinese Materia Medica 2015;40(24):4746-4751
This study collected demographic data, past history, personal history, family history, dosage, solvent, combined medication information of adverse reaction cases from a prospective, multi center, large sample intensive hospital monitoring, and found the influencing factors with cross-tab analysis. The results showed that in the medication group of 19-45, patients with allergic histories had a higher proportion in ADR; in the medication group of 46-65, male patients with allergic histories had a higher proportion in ADR; indication and non-indication group, patients of 19-45 years old, with combined medications and allergy histories had a higher proportion in ADR; Non-indication medication group, patients with combined medication, higher concentration, out-instruction solvent and dosage, had a higher proportion in ADR. So, the ADRs of Shenfu injection were related to the history of drug allergy, and also related to the indication, dosage, solvent, concentration when it was used.
Adult
;
Aged
;
Drug Hypersensitivity
;
etiology
;
Drugs, Chinese Herbal
;
adverse effects
;
Female
;
Humans
;
Injections
;
Male
;
Middle Aged
;
Prospective Studies
9.Clinical Values of serum CA125 and LPA determination in early diagnosis of ovarian cancer
Zongting YAN ; Ming HUANG ; Maolin ZHAO ; Aimei PANG
Chinese Journal of Primary Medicine and Pharmacy 2009;16(11):1993-1994
Objective To investigate clinical value of levels of CA125 and LPA as a panel for early diagnosis of ovarian cancer.Methods The levels of two tumor markers(CA125 and LPA)in serum were determined in 76 patients with ovarian cancer,35 patients with benign tumor and 29 healthy control.Results The results showed that the levels of two tumor markera in ovarian cancer patients were significantly higher than those in benign tumor patients and controls(P<0.05).Butuo siguificant difforences was loud betwcen benigutumor patient and coatrols.Conclusion Combined detection of the two markers represent a potential biomarker for diagnosis of epithelial ovarian cancer because of its diagnostic accuracy in ovarian cancer case.
10.Optimization of the Prescription of Traditional Chinese Medicine for MS by Uniform Design
Yan CHEN ; Jingfeng XU ; Jinping WANG ; Ming ZENG ; Weijuan ZHAO
China Pharmacy 2001;0(07):-
OBJECTIVE: To optimize the prescription of traditional Chinese medicine for motion sickness (MS).METHODS: Zingiber officinale,Herba pogostemonis,Aucklandia lappa were extracted respectively,and rotating-inducing MS mice were enrolled in uniform design.The prescription was optimized with MS index as the parameters.RESULTS: The optimal prescription was as follows:60 g Z.officinale,45 g Herba pogostemonis,5 g A.lappa.The extractive of prescription was significantly better than dimenhydrinate in the treatment of MS.CONCLUSION: MS index is a stable and sensitive parameters and it is suitable for screening and evaluation of anti-MS drugs.R.zingiberis,H.pogostemonis,A.lappq are potential drug for MS.